English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Background Trigeminal neuralgia (TN) is a chronic disorder characterized by paroxysmal facial pain. Adequate prophylactic drug therapy is often limited by the lack of efficacy and intolerance due to central nervous system side effects. Subcutaneous injections of botuinum toxin type A (BT-A) are a promising treatment option for patients with insatisfactory response to drug therapy or neurosurgical intervention. This is the study protocoll of a prospective, placebocontrolled, double blind clinical trial investigating the add-on therapy of subcutaneous of BT-A injections to standard treatment.

the journal of headache and pain

EHMTI-0202. Study protocol of BoTN: a randomized, double-blind, placebo-controlled trial to evaluate the efficacy and safety of botulinum toxin injections in the treatment of trigeminal neuralgia